Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > glioblastoma multiforme treatment market
Get a free sample of Glioblastoma Multiforme Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Glioblastoma Multiforme Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The competitive landscape of the market is characterized by the presence of established pharmaceutical companies that manufacture glioblastoma multiforme treatment products vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for glioblastoma multiforme treatment.
The company profile section includes both companies that have commercial drug available in the market as well as those that are into clinical phase development. Prominent players operating in the market are as mentioned below:
Amgen Inc., Amneal Pharmaceuticals, Curtana Pharmaceuticals, Denovo Biopharma, Eisai Co. Ltd. (Gliadel), F. Hoffmann La Roche Ltd (Genetech USA), Karyopharm Therapeutics, Merck & Co. Inc., and Novocure GmbH, among others.
North America glioblastoma multiforme treatment market held 39.5% revenue share in 2023 due to advanced technologies, key pharmaceutical companies, and government cancer research funding.
The hospitals segment in the market is expected to reach USD 2.5 billion by 2032 due to presence of advanced diagnostic tools, specialized neuro-oncology departments, and clinical trials.
Global glioblastoma multiforme treatment industry was valued at USD 2.9 billion in 2023 and is anticipated to register 8.6% CAGR between 2024 and 2032 due to the increasing incidence of glioblastoma along with rising awareness and early diagnosis of disease.